Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 20/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | VHL | P40337 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095375 | 1.00 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL25634793 | 0.95 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL21470681 | 0.93 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL21461991 | 0.93 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095316 | 0.93 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095452 | 0.92 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL21461988 | 0.92 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL25633166 | 0.88 | NAMPT (0.47) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095432 | 0.88 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9VHL | |
| SCHEMBL20095603 | 0.87 | NAMPT (0.54) | NAMPTCYP3A4CYP2C9VHL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEATTLE GENETICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314519-A1 | TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NME4, NNMT | NAMPT 1/4885CYP3A4 4869/4885CYP2C9 4851/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | NAMPT 1/4885CYP3A4 4869/4885CYP2C9 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.